The newest FDA-approved ADHD treatment is Simtriyo (centanafadine), a once-daily capsule for adults and children 6 and older that acts on three brain chemicals. Other recent approvals include Onyda XR, the first liquid non-stimulant for children; Qelbree (viloxazine), a non-stimulant now approved for adults too; and the stimulant Azstarys. Beyond medication, EndeavorRx is an FDA-authorized prescription video game, and the Monarch eTNS device is FDA-cleared for children. None of these is automatically the right fit: good ADHD care still starts with a careful diagnosis and follow-up with a qualified clinician.
New ADHD Treatments: Simtriyo Adds a Different Medication Option
The FDA approved Simtriyo as a once-daily extended-release capsule for ADHD in adults and children age 6 and older who weigh at least 20 kilograms (44 pounds). Its active ingredient, centanafadine, is the first approved norepinephrine, dopamine, and serotonin reuptake inhibitor, or NDSRI, for ADHD. In plain terms, it blocks transporters that normally take those chemical messengers back up after signaling. Its action is norepinephrine-dominant rather than an even three-way effect.
That mechanism is new, but an important label detail can be easy to miss. Although centanafadine was often discussed as a possible non-stimulant during development, the FDA classifies Simtriyo as a CNS stimulant. Its label carries boxed warnings about abuse and addiction potential and pediatric suicidal ideation. Commercial availability depends on DEA scheduling, so an approval does not necessarily mean a prescription can be filled immediately.
Trial Results Show Improvement, Not a Universal Winner
Four pivotal Phase 3 trials—two in adults with ADHD, one in adolescents, and one in children—found statistically significant symptom reductions with centanafadine compared with placebo. Pediatric studies used the ADHD-RS-5, while adult studies used the AISRS. Post-hoc analyses also suggested gains in executive-function areas such as time management, planning, task initiation, completion, and working memory.
The size of an average improvement matters when comparing choices. Across centanafadine trials, standardized effect sizes clustered from 0.24 to 0.40. That is below reported figures for amphetamine (0.79) and methylphenidate (0.49), and comparable with atomoxetine (0.45). In adolescent trials, the early difference at week 1 came from inattention; hyperactivity-impulsivity did not separate from placebo until week 3. Those findings can help frame a discussion, but they cannot predict how one person will respond.
Safety Questions Deserve a Full Conversation With the Prescriber
Medication decisions should weigh everyday effects as well as possible symptom improvement. In pediatric and adolescent centanafadine trials, commonly reported adverse events included decreased appetite, nausea, rash, headache, and abdominal pain. In adult trials, headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea were common.
A 52-week open-label adult safety study enrolled 662 people; 61.4% reported at least one treatment-emergent adverse event, mostly mild or moderate, and 12.3% discontinued because of an adverse event. Insomnia occurred in 8.0%, nausea in 7.7%, and diarrhea and headache in 7.0% each. Contact a doctor promptly about concerning mood changes, severe side effects, or questions about a boxed warning. A prescriber also needs to know about other medicines and health conditions before starting or changing ADHD medication.
How Simtriyo Compares With Established ADHD Medications
Stimulant medications based on methylphenidate or amphetamine remain first-line pharmacological treatment for ADHD in children, adolescents, and adults because decades of evidence support them and their average effects are larger. In an Otsuka-funded indirect comparison, centanafadine scored 6.58 points worse on the adult AISRS scale than lisdexamfetamine, a statistically significant difference.
| Option | What the facts show | Why a clinician may discuss it |
|---|---|---|
| Simtriyo (centanafadine) | Once-daily extended-release CNS stimulant; NDSRI mechanism | Another approved mechanism for people age 6 and older who meet the weight requirement |
| Azstarys | Stimulant combining a prodrug with immediate-release dexmethylphenidate | For patients age 6 and older; onset within 30 minutes and duration of up to 13 hours in one capsule |
| Atomoxetine or Qelbree | Non-stimulant choices; Qelbree is once daily and not a controlled substance | May be considered when stimulant effects are not tolerable or misuse risk is a concern |
| Guanfacine ER, clonidine ER, or Onyda XR | Alpha-2 adrenergic agonist options; Onyda XR is a nighttime liquid for children 6 and older | Can be used alone or, for some pediatric patients, alongside a stimulant |
Doctors Match the Treatment Plan to the Person, Not the Trend
A clinician usually considers the symptoms of ADHD, age, daily schedule, prior response, coexisting conditions, side effects, and access to medication. Stimulants may be less suitable when insomnia, appetite loss, anxiety, a substance-use history, tics, or another condition complicates treatment. Non-stimulants are not controlled substances and have negligible abuse potential; they can also offer steadier daily coverage for some people with ADHD.
Choosing does not have to mean finding a perfect answer on the first try. Doctors often follow a “start low, go slow” approach and adjust the dose step by step, so dose changes always belong with the prescriber. If a family cannot locate a prescribed stimulant, tell the prescriber rather than switching or stopping on their own. Mixed amphetamine salts and methylphenidate have both appeared on the FDA drug-shortage database.
Digital and Medication-Free Treatment Options Need Realistic Expectations
Medication is not the only support available to treat ADHD. Behavioral therapy and practical accommodations can be part of a treatment plan, whether or not medication is used. EndeavorRx is a prescription video game authorized for children ages 8 to 17 with primarily inattentive or combined-type ADHD and a demonstrated attention issue. In its trials, 68% of parents reported improvement in ADHD-related impairments after two months, with no serious adverse events. It is part of a therapeutic program, not a stand-alone substitute for ADHD medication. EndeavorOTC later launched for adults.
Some newer approaches are still research questions, not established care. The Monarch eTNS device delivers mild forehead stimulation during sleep and has FDA clearance for pediatric ADHD. Yet a 150-child phase 2b trial found no significant effect on ADHD symptoms, which challenges the earlier pilot result. TMS, tDCS with cognitive training, neurofeedback, and drugs targeting TAAR1 or mGluR are being studied. Early signals are not proof of benefit.
Three Common Myths Can Lead Families Off Course
- “New means stronger.” Centanafadine is a new mechanism, but its trial effect sizes were lower than those reported for common stimulant classes.
- “Non-medication care means no professional help.” Behavioral therapy, school or workplace support, and prescribed digital treatment can require coordinated clinical guidance.
- “FDA clearance proves a device will work for everyone.” The later eTNS trial did not find a significant symptom benefit, showing why confirmatory research matters.
ADHD can be managed without medication for some people, but the appropriate plan depends on the effects of ADHD, functioning, preferences, and available supports. See a doctor or qualified mental-health professional for an ADHD diagnosis, worsening symptoms, treatment side effects, or help building an individualized plan.
Frequently Asked Questions
What is centanafadine, and how does it work for ADHD?
Centanafadine is the active ingredient in Simtriyo. It is an approved NDSRI that blocks reuptake of norepinephrine, dopamine, and serotonin, with the strongest activity at norepinephrine transporters.
Who might benefit from Simtriyo?
It is approved for adults and children age 6 and older who weigh at least 20 kilograms. Whether it is appropriate depends on medical history, symptoms, safety considerations, and a clinician’s assessment.
How do doctors choose between stimulant and non-stimulant ADHD medications?
They consider effectiveness, side effects, prior response, coexisting conditions, substance-use history, daily coverage needs, and patient or family preferences. Stimulants are generally first-line, while non-stimulants may be useful in specific situations.
What are the newest medication-free treatments for ADHD?
Prescription digital treatment is available in limited settings, while eTNS, TMS, tDCS, and neurofeedback remain areas of mixed evidence or ongoing research. None should replace clinical advice.
Can ADHD be managed without medication?
Some people use behavioral therapy, accommodations, and other supports without medication. Discuss the risks, goals, and day-to-day impact with a qualified clinician rather than treating a new approach as a substitute for individualized care.
